InVivoMab anti-mouse CTLA-4 (CD152) BE0032-R005mg from Bio X Cell

Product Specs
ItemInVivoMab anti-mouse CTLA-4 (CD152)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0032-R005mg
Quantity5 mg
Applicationsin vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
TargetCTLA-4
IsotypeIgG
CloneUC10-4F10-11
HostArmenian hamster
NCBI Full Gene Namecytotoxic T-lymphocyte-associated protein 4
NCBI Gene AliasesCd152, Ctla-4, Ly-56
ClonalityMonoclonal
ImmunogenMouse CTLA-4 IgG2a fusion protein
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 6.5, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

(1) Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzymeNature biotechnologySeptember 1, 2018Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, et al.

(2) The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansioneLifeAugust 11, 2015Welten SP, Redeker A, Franken KL, Oduro JD, Ossendorp F, Čičin-Šain L, Melief CJ, Aichele P, Arens R.

(3) Three steps to breaking immune tolerance to lymphoma: a microparticle approachCancer immunology researchApril 1, 2015Makkouk A, Joshi VB, Lemke CD, Wongrakpanich A, Olivier AK, Blackwell SE, Salem AK, Weiner GJ.

(4) Immature dendritic cells convert anergic nonregulatory T cells into Foxp3- IL-10+ regulatory T cells by engaging CD28 and CTLA-4European journal of immunologyFebruary 1, 2015Pletinckx K, Vaeth M, Schneider T, Beyersdorf N, Hünig T, Berberich-Siebelt F, Lutz MB.

(5) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer modelsCancer researchSeptember 15, 2014Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

(6) Antimetastatic effects of blocking PD-1 and the adenosine A2A receptorCancer researchJuly 15, 2014Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

(7) Differential kinetics of antigen dependency of CD4+ and CD8+ T cellsJournal of immunology (Baltimore, Md. : 1950)April 15, 2014Rabenstein H, Behrendt AC, Ellwart JW, Naumann R, Horsch M, Beckers J, Obst R.

(9) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbsClinical cancer research : an official journal of the American Association for Cancer ResearchOctober 15, 2013Allard B, Pommey S, Smyth MJ, Stagg J.

(11) CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivoPLoS pathogensDecember 9, 2010Haque A, Best SE, Amante FH, Mustafah S, Desbarrieres L, de Labastida F, Sparwasser T, Hill GR, Engwerda CR.

(12) Reviving function in CD4+ T cells adapted to persistent systemic antigenJournal of immunology (Baltimore, Md. : 1950)October 1, 2009Noval Rivas M, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, Braun MY.

InVivoMab anti-mouse CTLA-4 (CD152)